Table 1.
Characteristics of subjects in the dataset (N = 193)
| Frequency (%) | Median | (Min, Max) | |
|---|---|---|---|
| Race |
|
|
|
| White |
131 (74.86%) |
|
|
| Non-White |
44 (25.14%) |
|
|
| Menstrual Status |
|
|
|
| Pre/Peri |
28 (15.56%) |
|
|
| Post |
154 (84.44%) |
|
|
| Histopathology |
|
|
|
| IDC |
161 (83.42%) |
|
|
| ILC |
13 (6.74%) |
|
|
| Medullary |
5 (2.59%) |
|
|
| Mucinous/Colloid |
6 (3.11%) |
|
|
| Tubular |
2 (1.04%) |
|
|
| Infiltrating Papillary |
2 (1.04%) |
|
|
| Adenocarcinoma |
2 (1.04%) |
|
|
| Carcinoma, NOS |
2 (1.04%) |
|
|
| Tumor Size |
|
|
|
| ≤ 2 cm |
97 (50.26%) |
|
|
| >2 cm and ≤ 5 cm |
96 (49.74%) |
|
|
| Stage |
|
|
|
| Stage I |
97 (50.26%) |
|
|
| Stage IIA |
96 (49.74%) |
|
|
| ER |
|
|
|
| ER+ |
141 (73.06%) |
|
|
| ER- |
52 (26.94%) |
|
|
| PR |
|
|
|
| PR+ |
85 (47.49%) |
|
|
| PR- |
94 (52.51%) |
|
|
| Ploidy |
|
|
|
| Diploid |
80 (41.45%) |
|
|
| Aneuploid |
113 (58.55%) |
|
|
| S-Phase |
|
|
|
| Low-Medium (≤10%) |
102 (53.13%) |
|
|
| High (> 10%) |
90 (46.88%) |
|
|
| RIL |
|
18.1% |
(0, 91.2) |
| HIN-1 |
|
13.6% |
(0, 98.4) |
| RASSF1A |
|
16.1% |
(0, 97.1) |
| CDH13 |
|
8.6% |
(0, 77.1) |
| Age |
|
62 years |
(30, 88) |
| Median follow-up time* | 152 months |
*Determined by scoring deaths as censored events and calculating follow-up time using Cox regression.